Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cyclin-dependent kinase 5 activator 2 (CDK5R2)
- Target
- CDK5R2
- Molecular classification
- Enzyme, Regulatory subunit, Protein kinase activator
01
Overview
Cyclin-dependent kinase 5 activator 2 (CDK5R2) is a neuron-specific protein encoded by the CDK5R2 gene. Its primary role is to bind and activate cyclin-dependent kinase 5 (CDK5), forming an active kinase complex essential for the development, differentiation, migration, and survival of neurons. CDK5R2 is one of two principal CDK5 activators, the other being CDK5R1 (p35); CDK5R2 (commonly known as p39) is most relevant in nervous tissue. Unlike classical cyclins, it defines a distinct family of kinase activators and is crucial for neuronal cytoskeletal organization, controlling growth cone dynamics, and modulating cell cycle-independent processes. Disruption of CDK5R2 or its complex formation can lead to severe neurodevelopmental abnormalities, and aberrant activity is implicated in certain neurodegenerative states.
- Other names
- CDK5R2NCK5AICDK5 activator 2p39nck5aiP39p39Ineuronal CDK5 activator isoformCyclin-dependent kinase 5 regulatory subunit 2cyclin-dependent kinase 5 activator 2
02
Mechanism of action
Activation of Cyclin-dependent kinase 5 (CDK5) through complex formation; modulation of CDK5's kinase activity, impacting substrates related to neuronal differentiation, migration, cytoskeleton, and signal transduction.
03
Biological functions
Activation of CDK5 kinaseRegulation of neuronal developmentSupport and organization of neuronal cytoskeletonControl of cell differentiation and migrationModulation of signaling pathways and cell cycle processes
04
Disease associations
Neurodevelopmental disordersNeurodegenerative diseases (e.g., linked to aberrant CDK5 activation)Primary microcephalyToe syndactyly, telecanthus, anogenital and renal malformations
05
Safety considerations
Targeting CDK5R2 or CDK5-capable complexes could disrupt critical neuronal development, migration, or survival processes, with risks including neurodevelopmental defects and neurotoxicity
06
Interacting drugs
None specifically documented for CDK5R2; drugs that target the CDK5 complex (often through its activators) may include experimental CDK5 inhibitors
07
Biomarkers
CDK5R2 expression could potentially serve as a biomarker for neuronal development, and CDK5 activity (often involving the CDK5R2 complex) may indicate neurodegenerative or neurodevelopmental dysfunction
Beyond the preview
Go deeper on Cyclin-dependent kinase 5 activator 2 (CDK5R2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cyclin-dependent kinase 5 activator 2 (CDK5R2).